Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?
Chemotherapy-induced premature ovarian insufficiency (POI) is one of the potential drawbacks of chemotherapy use of particular concern for newly diagnosed premenopausal breast cancer patients. Temporary ovarian suppression obtained pharmacologically with the administration of a gonadotropin-releasin...
Saved in:
Main Authors: | Matteo Lambertini (Author), François Richard (Author), Bastien Nguyen (Author), Giulia Viglietti (Author), Cynthia Villarreal-Garza (Author) |
---|---|
Format: | Book |
Published: |
SAGE Publishing,
2019-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of gonadotropin releasing hormone agonists (GNRHA) vs aromatase inhibitors on volume of uterine leiomyomas in premenopausal women
by: Uzma Hussain, et al.
Published: (2023) -
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review
by: Francesca Poggio, et al.
Published: (2019) -
Fertility preservation in an oncology patient who presented with positive human chorionic gonadotropin
by: Olivia Carpinello, M.D, et al.
Published: (2020) -
Gonadotropin-releasing hormone agonist for the preservation of ovarian function in survivors of haematopoietic stem cell transplantation for haematological diseases
by: Zhenhong Wang, et al.
Published: (2022) -
Risk of ovarian hyperstimulation syndrome in women with malignancies undergoing treatment with long-acting gonadotropin-releasing hormone agonist after controlled ovarian hyperstimulation for fertility preservation: a systematic review
by: Caroline Ingold, et al.
Published: (2023)